Retatrutide TRIUMPH Trial Updates: Latest Phase 3 Data
Latest updates from Eli Lilly's TRIUMPH Phase 3 trials for retatrutide, the triple-agonist GLP-1/GIP/glucagon medication. Expected timeline, efficacy data, and what it means for obesity treatment.
More on GLP-1 News
The Next Frontier
Retatrutide represents the next generation of obesity medications. Its triple-agonist mechanism—targeting GLP-1, GIP, and glucagon receptors simultaneously—may produce weight loss approaching what bariatric surgery achieves, while also addressing metabolic dysfunction.
Phase 2 Results That Stunned the Field
The Phase 2 trial of retatrutide, published in the New England Journal of Medicine in 2023, produced results that exceeded expectations across the obesity medicine community:
The most remarkable aspect of these results was that the weight loss trajectory had not plateaued by the end of the 48-week trial. With semaglutide and tirzepatide, weight loss typically begins to level off around weeks 60-68. The fact that retatrutide patients were still actively losing weight suggests that longer trials may show even more dramatic results.
The Triple-Agonist Advantage
What makes retatrutide different from existing medications is its activation of three hormone pathways simultaneously:
GLP-1 receptor: Appetite suppression
Same mechanism as semaglutide. Reduces hunger, slows gastric emptying, and improves blood sugar regulation. The foundation of the current GLP-1 revolution.
GIP receptor: Enhanced metabolic effects
Same additional mechanism as tirzepatide. Improves insulin sensitivity, may enhance fat metabolism, and appears to reduce some GI side effects.
Glucagon receptor: Energy expenditure boost
The novel component. Glucagon activation increases energy expenditure, promotes fat oxidation (particularly liver fat), and may help preserve muscle mass during weight loss. This could be the key to retatrutide's superior results.
TRIUMPH Phase 3 Program
The TRIUMPH Phase 3 program consists of multiple large-scale trials designed to confirm Phase 2 findings and support FDA approval:
TRIUMPH-1: Weight management in obesity
The primary obesity trial enrolling thousands of adults with BMI 30+ (or 27+ with comorbidities). Primary endpoint is percent body weight change at 72 weeks vs placebo. This is the pivotal trial for FDA approval.
TRIUMPH-2: Type 2 diabetes
Testing retatrutide as a diabetes treatment, measuring both A1C reduction and weight loss. If successful, this would support a diabetes indication alongside obesity.
TRIUMPH-3: MASH (metabolic dysfunction-associated steatohepatitis)
Testing retatrutide's ability to resolve liver inflammation and fibrosis. The glucagon component is particularly promising for liver health, as glucagon promotes hepatic fat oxidation.
Timeline and Expectations
Medical Disclaimer: This article is for educational purposes only. Retatrutide is an investigational medication not yet approved by the FDA. Do not discontinue current treatment in anticipation of future medications. Consult your healthcare provider about current treatment options.
Frequently Asked Questions
What is retatrutide?
Retatrutide is a triple-hormone receptor agonist that activates GLP-1, GIP, and glucagon receptors simultaneously. It is being developed by Eli Lilly and has shown the most weight loss of any obesity medication in Phase 2 trials—up to 24% body weight loss at 48 weeks.
How does retatrutide differ from tirzepatide?
Tirzepatide activates GLP-1 and GIP receptors (dual agonist). Retatrutide adds glucagon receptor activation (triple agonist). The glucagon component may increase energy expenditure and fat burning, potentially explaining the superior weight loss results in early trials.
When will retatrutide be available?
Retatrutide is currently in Phase 3 (TRIUMPH) trials. If results are positive and FDA review proceeds smoothly, the earliest potential approval would be 2027-2028. This timeline could shift based on trial outcomes and regulatory decisions.
What were the Phase 2 results?
In the Phase 2 trial, retatrutide at the highest dose (12mg) produced 24.2% body weight loss at 48 weeks—the most of any obesity drug at that time point. Notably, participants were still losing weight at 48 weeks, suggesting even greater losses at longer durations.
Start with Proven GLP-1 Treatment Today
While next-generation medications are in development, effective GLP-1 treatments are available now.
Get StartedSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).